Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTaP-HB-PRP~T vaccine + OPV
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Oral
01
Overview
This is an investigational vaccine combination consisting of a pentavalent DTaP-HB-PRP~T vaccine and an oral poliovirus vaccine (OPV), developed by Sanofi Pasteur. The pentavalent component is a biologic containing diphtheria toxoid, tetanus toxoid, acellular pertussis antigens (pertussis toxoid and filamentous hemagglutinin), hepatitis B surface antigen, and Haemophilus influenzae type b (Hib) capsular polysaccharide conjugated to tetanus toxoid (PRP~T). It is intended for the active immunization of infants against diphtheria, tetanus, pertussis, hepatitis B, and invasive Hib infections. In clinical trials, it is administered concomitantly with OPV to provide additional protection against poliomyelitis, following the WHO Expanded Programme on Immunization (EPI) schedule. This combination aims to simplify infant vaccination schedules by reducing the number of injections while maintaining immunogenicity comparable to established whole-cell pertussis-based pentavalent vaccines.
- Brand names
- SHAN5SHAN-5SHAN 5SHAN6SHAN-6SHAN 6
- Other names
- DTaP-HepB-PRP-T + OPVDTaP-HB-PRP~T vaccine + OPV-Sanofi Pasteur, a Sanofi Company-diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b infection
02
Targets
PRNP (Cellular Prion Protein)FHA (Filamentous hemagglutinin)HBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)
Beyond the preview
Go deeper on DTaP-HB-PRP~T vaccine + OPV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTaP-HB-PRP~T vaccine + OPV.